BTK and B-cell chronic lymphocytic leukemia: In the clinic, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor for B cell leukemia treatment, has been used in combination with CD19-CAR-T cells for chronic lymphocytic leukemia (CLL) therapy (29).